← Back to Clinical Trials
Recruiting NCT04599621

NCT04599621 Unstable Angina Pectoris in Comorbidity With Anxiety-depressive Syndrome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04599621
Status Recruiting
Phase
Sponsor Samarkand State Medical Institute
Condition Coronary Heart Disease
Study Type OBSERVATIONAL
Enrollment 3 participants
Start Date 2018-11-05
Primary Completion 2025-12-25

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10),Collection of blood samples to determine the level of uric acid

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3 participants in total. It began in 2018-11-05 with a primary completion date of 2025-12-25.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Introduction: Today it is necessary to emphasize that coronary heart disease is often associated with anxiety disorders. Research over the years has shown several and sometimes surprising links between coronary heart disease and mental illness, and has even suggested that both of these phenomena may actually cause each other. However, the exact nature of these links has not yet been clearly established. Methods: The study included 202 patients with coronary artery disease, of whom 42 patients were with stable angina pectoris, they participated as a control group, and 160 patients with unstable angina pectoris, who made up the main group. Among them there are 102 women and 100 men between the ages of 30 and 88. The average age was 63.75 ± 11.37 years. All study participants had blood in the morning on fasting after 8-12 hours of fasting from the cubital vein. Determination of the level of cytokines TNF-α, IL-1β, IL-4 and IL-10 in blood serum by enzyme-linked immunosorbent assay (ELISA). All participants in the study had blood drawn in the morning on fasting after 8-12 hours of fasting from the cubital vein. The level of uric acid was determined on the CYAN Start apparatus using a unified method. When examining patients with unstable angina pectoris were used: hospital anxiety and depression scale \[Kozlova S.N. 2013\]. And also the Spielberger-Khanin scale \[Psychiatry - Hoffman A.G. 2010\], developed by Spielberger Ch.D. and adapted by Yu.L. Khanin. to assess cognitive functions \[Psychiatry - Gofman A.G. 2010\].

Eligibility Criteria

Inclusion Criteria: * the presence of an established diagnosis in patients with coronary artery disease * unstable angina pectoris (NS). When making a diagnosis, the recommendations of ESH / ESC (2015) and RCO / WHO (2014) were used. * stable exertional angina (SSN) I-III FC. When making the diagnosis, the IHD classification was used, adopted at the IV Congress of Cardiologists of the Republic of Uzbekistan (2000), as well as in accordance with the recommendations of ESH / ESC (2019) and RCO / WHO (2017) Exclusion Criteria: * The patient's refusal to participate in the study; * Pregnancy and lactation; * Severe and unstable condition of the patient, making it difficult to conduct a questionnaire (for ethical reasons); * Acute violation of cerebral circulation; * History of acute or chronic psychosis; * The presence of concomitant acute diseases or chronic diseases in the acute stage. Throughout the study, all patients were assigned the right to voluntarily withdraw from the study at their own request, notifying the researcher in writing or orally.

Contact & Investigator

Central Contact

Zarina Nasirova, PhD

✉ zarina.nasirova.91@mail.ru

📞 +998902768950

Frequently Asked Questions

Who can join the NCT04599621 clinical trial?

This trial is open to participants of all sexes, studying Coronary Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04599621 currently recruiting?

Yes, NCT04599621 is actively recruiting participants. Contact the research team at zarina.nasirova.91@mail.ru for enrollment information.

Where is the NCT04599621 trial being conducted?

This trial is being conducted at Samarkand, Uzbekistan.

Who is sponsoring the NCT04599621 clinical trial?

NCT04599621 is sponsored by Samarkand State Medical Institute. The trial plans to enroll 3 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology